These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6543152)

  • 1. Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer.
    Vogl SE; Engstrom PF
    Cancer Treat Rep; 1984 Oct; 68(10):1273-5. PubMed ID: 6543152
    [No Abstract]   [Full Text] [Related]  

  • 2. [Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
    Mochizuki F; Tomioka K; Mizuno Y; Sato F; Yamagata T; Nagakawa Y; Kobari Y; Fujii M; Iwai S; Tanaka T
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):115-8. PubMed ID: 7826065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
    Chung YS; Yamashita Y; Inoue T; Matsuoka T; Nakata B; Onoda N; Maeda K; Sawada T; Kato Y; Shirasaka T; Sowa M
    Cancer; 1997 Jul; 80(1):1-7. PubMed ID: 9210702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of preoperative FPL (5-fluorouracil, cisplatin, leucovorin) therapy on patients with primary unresectable advanced gastric cancer].
    Tsujinaka T; Kato T; Shiozaki H; Murata A; Nishijima J; Kobayashi K; Inoue M; Miyata M; Kido Y; Mori T
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):303-6. PubMed ID: 8434971
    [No Abstract]   [Full Text] [Related]  

  • 5. [Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine].
    Satoh T; Tsushima K; Saitoh S; Tamura Y; Hizawa Y; Itoh J; Munakata A; Yamada Y
    Gan To Kagaku Ryoho; 1997 May; 24(7):879-82. PubMed ID: 9170530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
    Sasaki K; Hirata K; Denno R; Oikawa I; Mukaiya M; Hiraike N; Yagihashi A; Takasaka H; Katsuramaki T; Yamashiro K; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):959-64. PubMed ID: 9212804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three advanced gastric cancer patients successfully treated by combination therapy of paclitaxel and cisplatin].
    Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Ohkawa K; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Katsuta M; Yamashita K; Tajiri T
    Gan To Kagaku Ryoho; 2007 May; 34(5):769-72. PubMed ID: 17496455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced gastric cancer associated with DIC successfully treated with 5-FU and cisplatin: a case report.
    Matsumoto S; Kiba T; Numata K; Ihata Y; Morita K; Kitamura T; Saito S; Nakatani Y; Tanaka K; Sekihara H
    Hepatogastroenterology; 2002; 49(43):153-6. PubMed ID: 11941941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
    Sencan O; Buyukcelik A; Yalcin B; Boruban MC; Akbulut H; Demirkazik A; Senler FC; Onur H; Icli F
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):26-32. PubMed ID: 18181888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
    Poorter RL; Bakker PJ; Fockens P; Taat CW; Bartelsman JF; Veenhof CH
    J Infus Chemother; 1996; 6(2):87-91. PubMed ID: 8809656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
    Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization].
    Kubo Y; Kurita A; Saeki T; Yokoyama N; Tanada M; Takiyama W; Saeki H; Takashima S
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1951-7. PubMed ID: 8978803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer.
    Kikuyama S; Inada T; Oyama R; Ogata Y
    Anticancer Res; 2002; 22(6B):3633-6. PubMed ID: 12552968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment of two patients with advanced gastric cancer by neoadjuvant chemotherapy with EAP regimen].
    Matsumura T; Ohnoshi T; Ueoka H; Kiura K; Tabata M; Genba K; Chikamori M; Ikubo S; Matsuo K; Kimura I
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):261-4. PubMed ID: 8311499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy of 5-FU and low dose CDDP for advanced and recurrence gastric cancer].
    Chung YS; Yamashita Y; Nakata B; Nitta A; Inoue T; Hirayama K; Ogawa M; Kubo T; Kato Y; Shirasaka T
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):149-51. PubMed ID: 7826072
    [No Abstract]   [Full Text] [Related]  

  • 19. [Advanced and recurrent gastric carcinoma: combination chemotherapy with etoposide (E), adriamycin (A), cisplatin (P) = EAP].
    Ohwada S; Miyamoto Y; Takeshita M; Fujii T; Uchida O; Tanahasi Y; Aoyagi H; Izuo M
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3487-9. PubMed ID: 2802641
    [No Abstract]   [Full Text] [Related]  

  • 20. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.